A key reveal from this past year of pandemic response is how timely, accurate and accessible data can inform and guide health system decision-making. Good data, effectively applied, can transform clinical outcomes. The UK’s recent RECOVERY (Randomized Evaluation of COVID-19 Therapies) trial is a case in point: it found that a common steroid drug, dexamethasone, although not effective in all patients, still reduced mortality by one-third for the sickest patients, providing an evidence-based alternative to costly hospitalizations.
Pacifying A Pandemic With Numbers
Big Data’s Best And Brightest Join To Bring Better Solutions To The Clinic
Powered by prominent global health philanthropies and the UK’s world-class collaborative capabilities in disease surveillance, the new International COVID-19 Data Alliance (ICODA) is gearing up to address a crucial – and yet unanswered – policy question for public health: can sharing data curated from a diversity of sources provide the hard evidence needed to improve patient outcomes against the virus – not just for today’s pandemic, but for future ones as well? Much will depend on a robust response from big pharma.
More from COVID-19
• By
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
• By
A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.
• By
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
• By
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.
More from In Vivo
• By
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
• By
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.